StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.

A number of other research firms have also issued reports on CTLT. Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a report on Thursday, January 25th. Royal Bank of Canada reaffirmed a sector perform rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reissued a neutral rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Stephens restated an equal weight rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Hold and a consensus target price of $52.46.

Catalent Price Performance

Shares of NYSE CTLT opened at $56.05 on Friday. The firm’s 50-day simple moving average is $56.81 and its 200 day simple moving average is $48.30. The stock has a market cap of $10.14 billion, a P/E ratio of -8.24, a P/E/G ratio of 5.98 and a beta of 1.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent has a fifty-two week low of $31.45 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the firm posted $0.62 earnings per share. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. Equities analysts expect that Catalent will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Gladius Capital Management LP acquired a new stake in shares of Catalent during the 3rd quarter valued at $28,000. Exchange Traded Concepts LLC purchased a new position in Catalent in the third quarter valued at about $31,000. GAMMA Investing LLC acquired a new position in Catalent in the 4th quarter worth about $33,000. Cary Street Partners Investment Advisory LLC raised its stake in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after purchasing an additional 709 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new stake in shares of Catalent during the 4th quarter valued at about $46,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.